Vladimir Miloradović
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vladimir Miloradović has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Boris Dzudovic
Medical Faculty of the Military Medical Academy, University of Defence, 17 Crnotravska, 11000 Belgrade, Serbia
7 shared publications - Slobodan Obradovic
Medical Faculty of the Military Medical Academy, University of Defence, 17 Crnotravska, 11000 Belgrade, Serbia
7 shared publications - Jovan Matijasevic
Clinic for Intensive Care Medicine and Pulmonary Vascular Diseases, Institute for Pulmonary Diseases Vojvodina, 21204 Sremska Kamenica, Serbia
6 shared publications - Sonja Šalinger-Martinović
Clinic of Cardiology, Clinical Center Nis, 18000 Nis, Serbia
6 shared publications - Aleksandar Neskovic
Clinic of Cardiology, University Clinical Center Zemun, 11080 Belgrade, Serbia
5 shared publications Ana Kovačević-Kuzmanović
4 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 20
Sex-related differences in echocardiography parameters for predicting in-hospital mortality in patients with acute pulmonary embolism
Background: Risk stratification of acute pulmonary embolism (PE) is primarily based on systolic arterial pressure, right ventricular (RV) function, and cardiac troponin levels. Objectives: To investigate sex-related differences in simple RV echocardiographic parameters for predicting all-cause in-hospital mortality in acute PE. Design: Multicenter, observational, retrospective, registry-based cohort study. Methods: We analyzed data from the Regional Pulmonary Embolism Registry, including consecutive patients with acute PE confirmed by computed tomography pulmonary angiography between January 2015 and January 2026. Of 2776 patients, 2408 had at least one RV echocardiographic parameter measured at admission (RV diastolic diameter, RV systolic pressure, tricuspid annular plane systolic excursion [TAPSE], and ratio TAPSE/RV systolic pressure). Multivariable Cox regression adjusted for age, sex-specific differences, and shock at admission (systolic arterial pressure 16 mm for men, enabling discrimination between low- and high-risk patients. Mortality was 10.2% versus 0.9% in women (≤19 vs. >19 mm, p16 mm, p=0.001). In women, TAPSE >19 mm identified a subgroup with very low in-hospital mortality (1.4%) and an excellent negative predictive value (98.6%). Conclusion: In patients with acute PE, TAPSE measured at admission in women, but not in men, was the only echocardiographic parameter independently associated with all-cause in-hospital mortality.
- 10 September 2026
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 20
Open AccessSex-related differences in echocardiography parameters for predicting in-hospital mortality in patients with acute pulmonary embolism
Background: Risk stratification of acute pulmonary embolism (PE) is primarily based on systolic arterial pressure, right ventricular (RV) function, and cardiac troponin levels. Objectives: To investigate sex-related differences in simple RV echocardiographic parameters for predicting all-cause in-hospital mortality in acute PE. Design: Multicenter, observational, retrospective, registry-based cohort study. Methods: We analyzed data from the Regional Pulmonary Embolism Registry, including consecutive patients with acute PE confirmed by computed tomography pulmonary angiography between January 2015 and January 2026. Of 2776 patients, 2408 had at least one RV echocardiographic parameter measured at admission (RV diastolic diameter, RV systolic pressure, tricuspid annular plane systolic excursion [TAPSE], and ratio TAPSE/RV systolic pressure). Multivariable Cox regression adjusted for age, sex-specific differences, and shock at admission (systolic arterial pressure 16 mm for men, enabling discrimination between low- and high-risk patients. Mortality was 10.2% versus 0.9% in women (≤19 vs. >19 mm, p16 mm, p=0.001). In women, TAPSE >19 mm identified a subgroup with very low in-hospital mortality (1.4%) and an excellent negative predictive value (98.6%). Conclusion: In patients with acute PE, TAPSE measured at admission in women, but not in men, was the only echocardiographic parameter independently associated with all-cause in-hospital mortality.
- Open Access
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srpski medicinski casopis Lekarske komore
- Vol. 7 (3) , 352-364
Insomnia as a risk factor in cardiac patients and the treatment approach
Introduction/Objective: Insomnia is a common sleep disorder that extends beyond the subjective feeling of poor sleep and represents a state of persistent physiological hyperarousal with important cardiovascular consequences. This review aimed to summarize the pathophysiological links between insomnia and cardiovascular disease and to compare the clinical implications of benzodiazepines and Z-hypnotics in the treatment of insomnia in cardiac patients. Methods: Using a descriptive-comparative approach, we analyzed review articles, meta-analyses, cohort studies, and observational studies addressing the relationship between insomnia, cardiovascular outcomes, and pharmacological treatment, with particular focus on differences between benzodiazepines and Z-hypnotics in cardiac patients. Results: The available evidence indicates that insomnia, through autonomic, neuroendocrine, inflammatory, and metabolic dysregulation, contributes to the development of hypertension, atrial fibrillation, and heart failure, with the greatest risk observed in insomnia with objectively short sleep duration. Longitudinal studies further suggest that persistent insomnia symptoms are associated with greater cardiovascular burden. In therapeutic terms, benzodiazepines in cardiac patients are associated with higher rates of adverse events, including heart failure rehospitalization, sudden cardiac arrest, and cardiovascular mortality, whereas available data on Z-hypnotics suggest a more favorable or neutral profile. Conclusion: Insomnia is a clinically important yet often overlooked cardiovascular risk factor. In cardiac patients, its recognition and treatment should be part of a comprehensive clinical approach, prioritizing non-pharmacological measures and carefully selected pharmacotherapy. When drug treatment is necessary, Z-hypnotics may be considered a more favorable alternative to benzodiazepines, with zopiclone standing out because of its pharmacological and clinical characteristics.
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srpski medicinski casopis Lekarske komore
- Vol. 7 (3) , 352-364
Open AccessInsomnia as a risk factor in cardiac patients and the treatment approach
Introduction/Objective: Insomnia is a common sleep disorder that extends beyond the subjective feeling of poor sleep and represents a state of persistent physiological hyperarousal with important cardiovascular consequences. This review aimed to summarize the pathophysiological links between insomnia and cardiovascular disease and to compare the clinical implications of benzodiazepines and Z-hypnotics in the treatment of insomnia in cardiac patients. Methods: Using a descriptive-comparative approach, we analyzed review articles, meta-analyses, cohort studies, and observational studies addressing the relationship between insomnia, cardiovascular outcomes, and pharmacological treatment, with particular focus on differences between benzodiazepines and Z-hypnotics in cardiac patients. Results: The available evidence indicates that insomnia, through autonomic, neuroendocrine, inflammatory, and metabolic dysregulation, contributes to the development of hypertension, atrial fibrillation, and heart failure, with the greatest risk observed in insomnia with objectively short sleep duration. Longitudinal studies further suggest that persistent insomnia symptoms are associated with greater cardiovascular burden. In therapeutic terms, benzodiazepines in cardiac patients are associated with higher rates of adverse events, including heart failure rehospitalization, sudden cardiac arrest, and cardiovascular mortality, whereas available data on Z-hypnotics suggest a more favorable or neutral profile. Conclusion: Insomnia is a clinically important yet often overlooked cardiovascular risk factor. In cardiac patients, its recognition and treatment should be part of a comprehensive clinical approach, prioritizing non-pharmacological measures and carefully selected pharmacotherapy. When drug treatment is necessary, Z-hypnotics may be considered a more favorable alternative to benzodiazepines, with zopiclone standing out because of its pharmacological and clinical characteristics.
- 1 January 2025
- Published by University Library in Kragujevac
- p. 320-323
Approaches in the Treatment of Uncontrolled Hypertension
Despite the availability of antihypertensive drugs, many patients worldwide have uncontrolled hypertension (1,2). In this regard, the term „resistant hypertension“ was introduced, with a prevalence of 10%-20% in hypertensive patients (3). According to the current guidelines of the European Association of Cardiology, hypertension is defined as resistant when the treatment strategy, which includes appropriate lifestyle measures and treatment with maximum or maximally tolerated doses of diuretics (thiazides and thiazide-like diuretics), blockers of the renin-angiotension-aldosterone system (RAAS) and calcium channel blockers, fails to lower systolic arterial pressure <140 mm Hg and/or diastolic arterial pressure <90 mm Hg (4). Compared to patients who achieve adequate blood pressure control with antihypertensives, patients with resistant hypertension have a worse prognosis and consequently a higher risk of myocardial infarction, stroke and end-stage renal disease, with two to six times higher mortality (5,6). The cause of uncontrolled hypertension is usually identified in secondary hypertension), with a prevalence of up to 30% among patients with resistant hypertension (7,8). In addition to secondary hypertension, it is important to rule out pseudoresistant hypertension, including that caused by non-adherence to treatment (4). In this regard, large observational studies have found that within one year, approximately 50% of patients stop taking antihypertensive medications for various reasons, such as inadequacy, adverse drug reactions, and socioeconomic variables (9). Uncontrolled hypertension is significantly associated with increased sympathetic activity, which can be caused by afferent signals originating from the kidneys and the influence of sympathetic tone by stimulating hypothalamic centers (10). Chronic activation of renal sympathetic nerves is key in the pathogenesis of hypertension through various mechanisms (reabsorption of salt and water in renal tubules, reduction of renal perfusion and consequently glomerular filtration rate, activation of the RAAS cascade) (9). Consequently, renal denervation (RDN) has emerged as a therapeutic option in conditions of overactive central sympathetic nervous system (10). This chapter explores the role of SGLT2i in the treatment of hypertension, with a focus on their mechanisms of action, recent clinical evidence, and future implications. The introduction of this drug class may represent a paradigm shift in the management of UAH, offering new opportunities for more effective and individualized therapeutic strategies.
- 1 January 2025
- Published by University Library in Kragujevac
- p. 320-323
Approaches in the Treatment of Uncontrolled Hypertension
Despite the availability of antihypertensive drugs, many patients worldwide have uncontrolled hypertension (1,2). In this regard, the term „resistant hypertension“ was introduced, with a prevalence of 10%-20% in hypertensive patients (3). According to the current guidelines of the European Association of Cardiology, hypertension is defined as resistant when the treatment strategy, which includes appropriate lifestyle measures and treatment with maximum or maximally tolerated doses of diuretics (thiazides and thiazide-like diuretics), blockers of the renin-angiotension-aldosterone system (RAAS) and calcium channel blockers, fails to lower systolic arterial pressure <140 mm Hg and/or diastolic arterial pressure <90 mm Hg (4). Compared to patients who achieve adequate blood pressure control with antihypertensives, patients with resistant hypertension have a worse prognosis and consequently a higher risk of myocardial infarction, stroke and end-stage renal disease, with two to six times higher mortality (5,6). The cause of uncontrolled hypertension is usually identified in secondary hypertension), with a prevalence of up to 30% among patients with resistant hypertension (7,8). In addition to secondary hypertension, it is important to rule out pseudoresistant hypertension, including that caused by non-adherence to treatment (4). In this regard, large observational studies have found that within one year, approximately 50% of patients stop taking antihypertensive medications for various reasons, such as inadequacy, adverse drug reactions, and socioeconomic variables (9). Uncontrolled hypertension is significantly associated with increased sympathetic activity, which can be caused by afferent signals originating from the kidneys and the influence of sympathetic tone by stimulating hypothalamic centers (10). Chronic activation of renal sympathetic nerves is key in the pathogenesis of hypertension through various mechanisms (reabsorption of salt and water in renal tubules, reduction of renal perfusion and consequently glomerular filtration rate, activation of the RAAS cascade) (9). Consequently, renal denervation (RDN) has emerged as a therapeutic option in conditions of overactive central sympathetic nervous system (10). This chapter explores the role of SGLT2i in the treatment of hypertension, with a focus on their mechanisms of action, recent clinical evidence, and future implications. The introduction of this drug class may represent a paradigm shift in the management of UAH, offering new opportunities for more effective and individualized therapeutic strategies.
- Open Access
- 1 December 2024
- Published by University of Nis Faculty of Medicine in AFMN Biomedicine
- Vol. 42 (1) , 61-73
Refining risk stratification in pulmonary embolism: Integrating glomerular filtration rate and simplified pulmonary embolism severity index as a potent predictor of patient survival
Patients classified as belonging to simplified pulmonary embolism severity index (sPESI) class 0 are considered to have low-risk pulmonary embolism (PE). Yet, certain laboratory and echocardiographic parameters not accounted for in the sPESI score might suggest a likelihood of worse outcomes in PE cases. This study seeks to determine if the prognostic value of the sPESI score in acute PE can be improved, refined, and optimised by incorporating brain natriuretic peptide (BNP) and troponin I (TnI) levels, echocardiographic parameters, or glomerular filtration rate. The study encompassed 1,201 consecutive patients diagnosed with PE, confirmed by multidetector computed tomography (MDCT). Upon admission, each patient underwent an echocardiography exam, and blood samples were taken to measure B-type natriuretic peptide (BNP), troponin I (TnI), creatinine, and other routine laboratory markers. The in-hospital mortality rate was 11.5%. The patients were categorized into three groups using the three-level sPESI model: sPESI 0, sPESI 1, and sPESI ≥ 2. Statistically significant differences were found among these groups regarding mortality rates, TnI values, BNP levels, estimated glomerular filtration rate (eGFR), and the presence of right ventricular dysfunction (RVD). Cox regression analysis identified eGFR as the most reliable predictor of 30-day all-cause mortality [HR 2.24 (CI 1.264-3.969); p = 0.006] across all sPESI categories. However, incorporating TnI, BNP, or RVD did not improve risk prediction beyond the three-level sPESI model. Renal dysfunction at the time of admission is closely related to an elevated risk of in-hospital mortality in patients with acute PE. The three-level sPESI score offers a more accurate method for prognostic stratification in these patients.
- 1 December 2024
- Published by University of Nis Faculty of Medicine in AFMN Biomedicine
- Vol. 42 (1) , 61-73
Open AccessRefining risk stratification in pulmonary embolism: Integrating glomerular filtration rate and simplified pulmonary embolism severity index as a potent predictor of patient survival
Patients classified as belonging to simplified pulmonary embolism severity index (sPESI) class 0 are considered to have low-risk pulmonary embolism (PE). Yet, certain laboratory and echocardiographic parameters not accounted for in the sPESI score might suggest a likelihood of worse outcomes in PE cases. This study seeks to determine if the prognostic value of the sPESI score in acute PE can be improved, refined, and optimised by incorporating brain natriuretic peptide (BNP) and troponin I (TnI) levels, echocardiographic parameters, or glomerular filtration rate. The study encompassed 1,201 consecutive patients diagnosed with PE, confirmed by multidetector computed tomography (MDCT). Upon admission, each patient underwent an echocardiography exam, and blood samples were taken to measure B-type natriuretic peptide (BNP), troponin I (TnI), creatinine, and other routine laboratory markers. The in-hospital mortality rate was 11.5%. The patients were categorized into three groups using the three-level sPESI model: sPESI 0, sPESI 1, and sPESI ≥ 2. Statistically significant differences were found among these groups regarding mortality rates, TnI values, BNP levels, estimated glomerular filtration rate (eGFR), and the presence of right ventricular dysfunction (RVD). Cox regression analysis identified eGFR as the most reliable predictor of 30-day all-cause mortality [HR 2.24 (CI 1.264-3.969); p = 0.006] across all sPESI categories. However, incorporating TnI, BNP, or RVD did not improve risk prediction beyond the three-level sPESI model. Renal dysfunction at the time of admission is closely related to an elevated risk of in-hospital mortality in patients with acute PE. The three-level sPESI score offers a more accurate method for prognostic stratification in these patients.
- Open Access
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srce i krvni sudovi
- Vol. 43 (4) , 5-9
Who are the normotensive acute pulmonary embolism patients with right ventricle dysfunction and normal cardiac troponin blood level?
Background. Current guidelines for acute pulmonary embolism (PE) management classify patients with heart right ventricle dysfunction (RVD) who do not have elevated cardiac troponin (cTn) blood levels as intermediate low risk patients. The aim of this investigation is to study the characteristics of these patients and the role of pre-existing cardiovascular diseases for the RVD. Methodology. Out of 1675 patients with acute PE from the regional PE registry, we included 353 normotensive patients who had echocardiography imaging at presentation to hospital and normal blood levels of cTn. Patients were divided into low risk PE if they hadn't RVD and intermediate-low risk if they had RVD and their characteristics were compared. Results. A 216 patients with low risk PE were significantly younger than 137 patients with intermediate-low risk. Arterial hypertension, chronic heart failure with reduced ejection fraction, coronary disease and diabetes mellitus type 2 were all significantly more prevalent in patients with intermediate-low risk (p<0.001 for all comparisons) compare to low risk patients (77.4% vs 47.6%, p<0.001 for the presence of at least one of the four mentioned cardiovascular diseases). The age and sex adjusted odds ratio to have at least one of the mentioned cardiovascular diseases and intermediatelow PE was 2.954 (95%CI 1.658-5.266). Conclusions. The majority of normotensive acute PE patients with RVD and normal cTn are actually chronic cardiovascular patients.
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srce i krvni sudovi
- Vol. 43 (4) , 5-9
Open AccessWho are the normotensive acute pulmonary embolism patients with right ventricle dysfunction and normal cardiac troponin blood level?
Background. Current guidelines for acute pulmonary embolism (PE) management classify patients with heart right ventricle dysfunction (RVD) who do not have elevated cardiac troponin (cTn) blood levels as intermediate low risk patients. The aim of this investigation is to study the characteristics of these patients and the role of pre-existing cardiovascular diseases for the RVD. Methodology. Out of 1675 patients with acute PE from the regional PE registry, we included 353 normotensive patients who had echocardiography imaging at presentation to hospital and normal blood levels of cTn. Patients were divided into low risk PE if they hadn't RVD and intermediate-low risk if they had RVD and their characteristics were compared. Results. A 216 patients with low risk PE were significantly younger than 137 patients with intermediate-low risk. Arterial hypertension, chronic heart failure with reduced ejection fraction, coronary disease and diabetes mellitus type 2 were all significantly more prevalent in patients with intermediate-low risk (p<0.001 for all comparisons) compare to low risk patients (77.4% vs 47.6%, p<0.001 for the presence of at least one of the four mentioned cardiovascular diseases). The age and sex adjusted odds ratio to have at least one of the mentioned cardiovascular diseases and intermediatelow PE was 2.954 (95%CI 1.658-5.266). Conclusions. The majority of normotensive acute PE patients with RVD and normal cTn are actually chronic cardiovascular patients.
- Open Access
- 1 January 2024
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 81 (5) , 310-317
Sex differences in the prognostic value of computed tomography pulmonary angiography parameters for intrahospital acute pulmonary embolism-related death
Background/Aim. Multidetector computed tomography pulmonary angiography (MCTPA) has emerged as the most suitable method for diagnosing acute pulmonary embolism (APE) in hemodynamically stable patients. In addition to its diagnostic role, MCTPA facilitates the measurement and calculation of certain parameters that can be used as prognostic markers for outcomes in APE. Since the introduction of the method, there have been a lot of studies that pointed out there may be a significant difference in the prognostic value of MCTPA for APE concerning sex. Methods. The study population consisted of consecutive patients with a diagnosis of APE confirmed by MCTPA. Positive MCTPA findings and a diagnosis of APE were established if the patient had at least one segmental artery thrombus. APE severity was estimated using the simplified Pulmonary Embolism Severity Index (sPESI). All-cause and APE-related intrahospital deaths were the coprimary outcomes of this study. Results. In total, 1,612 patients were enrolled in the study (750 men and 862 women). Women with a centrally positioned pulmonary thrombus detected on MCTPA were more likely to die from PE-related death than those without one (10.4% vs. 4.2%, respectively; p = 0.016). Women with a right ventricle (RV) and left ventricle (LV) diameter ratio (RV/LV) > 1 died almost twice as often as those with a ratio ? 1 (15.5% vs. 8.6%, respectively; p = 0.017). Women with an RV/LV > 1 detected with MCTPA were significantly more likely to die from PE than those with a ratio ? 1 (11% vs. 5.2%, respectively; p = 0.017). Women who died from PE-related causes had a significantly higher value of the embolic burden score system (EBSS) than did the surviving women (18.00 vs. 11.00, respectively; p = 0.025). Independently of age, sPESI, and renal function, the presence of a central thrombus [odds ratio (OR) 2.278, 95% confidence interval (CI): 1.050?4.944, p = 0.037] and the RV/LV ratio > 1 (OR 2.015, 95% CI: 1.042?3.893, p = 0.037) were associated with intrahospital PE-related death in women. Conclusion. In women, MCTPA parameters, a centrally placed thrombus, the RV/LV ratio, and the EBSS had prognostic significance for PE-related mortality. The RV/LV ratio had prognostic significance for all-cause intrahospital mortality. In men, the MCTPA parameters had no prognostic significance for both overall and PE-related mortality.
- 1 January 2024
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 81 (5) , 310-317
Open AccessSex differences in the prognostic value of computed tomography pulmonary angiography parameters for intrahospital acute pulmonary embolism-related death
Background/Aim. Multidetector computed tomography pulmonary angiography (MCTPA) has emerged as the most suitable method for diagnosing acute pulmonary embolism (APE) in hemodynamically stable patients. In addition to its diagnostic role, MCTPA facilitates the measurement and calculation of certain parameters that can be used as prognostic markers for outcomes in APE. Since the introduction of the method, there have been a lot of studies that pointed out there may be a significant difference in the prognostic value of MCTPA for APE concerning sex. Methods. The study population consisted of consecutive patients with a diagnosis of APE confirmed by MCTPA. Positive MCTPA findings and a diagnosis of APE were established if the patient had at least one segmental artery thrombus. APE severity was estimated using the simplified Pulmonary Embolism Severity Index (sPESI). All-cause and APE-related intrahospital deaths were the coprimary outcomes of this study. Results. In total, 1,612 patients were enrolled in the study (750 men and 862 women). Women with a centrally positioned pulmonary thrombus detected on MCTPA were more likely to die from PE-related death than those without one (10.4% vs. 4.2%, respectively; p = 0.016). Women with a right ventricle (RV) and left ventricle (LV) diameter ratio (RV/LV) > 1 died almost twice as often as those with a ratio ? 1 (15.5% vs. 8.6%, respectively; p = 0.017). Women with an RV/LV > 1 detected with MCTPA were significantly more likely to die from PE than those with a ratio ? 1 (11% vs. 5.2%, respectively; p = 0.017). Women who died from PE-related causes had a significantly higher value of the embolic burden score system (EBSS) than did the surviving women (18.00 vs. 11.00, respectively; p = 0.025). Independently of age, sPESI, and renal function, the presence of a central thrombus [odds ratio (OR) 2.278, 95% confidence interval (CI): 1.050?4.944, p = 0.037] and the RV/LV ratio > 1 (OR 2.015, 95% CI: 1.042?3.893, p = 0.037) were associated with intrahospital PE-related death in women. Conclusion. In women, MCTPA parameters, a centrally placed thrombus, the RV/LV ratio, and the EBSS had prognostic significance for PE-related mortality. The RV/LV ratio had prognostic significance for all-cause intrahospital mortality. In men, the MCTPA parameters had no prognostic significance for both overall and PE-related mortality.
- Open Access
- 1 September 2023
- Published by Walter de Gruyter GmbH in Experimental and Applied Biomedical Research (EABR)
- Vol. 24 (3) , 199-205
Prognostic Value of D-Dimer in Younger Patients with Pulmonary Embolism
Sciendo provides publishing services and solutions to academic and professional organizations and individual authors. We publish journals, books, conference proceedings and a variety of other publications.
- 1 September 2023
- Published by Walter de Gruyter GmbH in Experimental and Applied Biomedical Research (EABR)
- Vol. 24 (3) , 199-205
Open AccessPrognostic Value of D-Dimer in Younger Patients with Pulmonary Embolism
Sciendo provides publishing services and solutions to academic and professional organizations and individual authors. We publish journals, books, conference proceedings and a variety of other publications.
- Open Access
- 1 January 2023
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 151 (00) , 72
Cardiac arrest and repeated ST-segment elevation caused by initially unrecognized coronary vasospasm
Introduction. Coronary artery spasm (CAS) is defined as a transient vasoconstriction of an epicardial coronary artery with a total or subtotal vessel occlusion, causing myocardial ischemia. Although the overall incidence of CAS during coronary angiography is estimated to be between 0.3% and 1%, CAS remains an underdiagnosed and undertreated cause of acute cardiac events. Case outline. In this article, we report a case of a 62-year-old male presenting with cardiac arrest and repeated ST-segment elevations during chest pain episodes, caused by initially unrecognized CAS. Although percutaneous coronary intervention (PCI) is generally not recommended for the treatment of CAS, due to clinical manifestations and the presence of underlying flow-limiting stenosis, we decided to perform PCI of the left anterior descending coronary artery. During the two-year-follow up period, the patient reported no chest pains nor exercise limitations at regular outpatient controls. Conclusion. Coronary artery spasms should be considered an unrecognized cause of refractory angina, acute coronary syndrome, malignant arrhythmia, and even cardiac arrest. Although medical therapy is the first option for CAS treatment, PCI could be a safe and effective approach in selected patients.
- 1 January 2023
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 151 (00) , 72
Open AccessCardiac arrest and repeated ST-segment elevation caused by initially unrecognized coronary vasospasm
Introduction. Coronary artery spasm (CAS) is defined as a transient vasoconstriction of an epicardial coronary artery with a total or subtotal vessel occlusion, causing myocardial ischemia. Although the overall incidence of CAS during coronary angiography is estimated to be between 0.3% and 1%, CAS remains an underdiagnosed and undertreated cause of acute cardiac events. Case outline. In this article, we report a case of a 62-year-old male presenting with cardiac arrest and repeated ST-segment elevations during chest pain episodes, caused by initially unrecognized CAS. Although percutaneous coronary intervention (PCI) is generally not recommended for the treatment of CAS, due to clinical manifestations and the presence of underlying flow-limiting stenosis, we decided to perform PCI of the left anterior descending coronary artery. During the two-year-follow up period, the patient reported no chest pains nor exercise limitations at regular outpatient controls. Conclusion. Coronary artery spasms should be considered an unrecognized cause of refractory angina, acute coronary syndrome, malignant arrhythmia, and even cardiac arrest. Although medical therapy is the first option for CAS treatment, PCI could be a safe and effective approach in selected patients.
- Open Access
- 1 January 2022
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srce i krvni sudovi
- Vol. 41 (4) , 163-167
What we have learned from the Regional Pulmonary Embolism Registry (REPER)?
Introduction. The management of acute pulmonary embolism (PE) is still full of controversies, and the number of randomized trials in this field is relatively small. For the individual doctor and the health system who deal with acute pulmonary embolism it is very important to analyze the number of treated patients, hospital and out of hospital mortality and morbidity, how the patients' treated, what are the most important obstacles for the management of the disease. Methods. Here, we present the Regional PE registry (REPER), in brief its development, purposes and the scientific results published in the journals on the scientific citation list, doctor thesis and studies accepted and presented at the European Society of Cardiology annual Congress. This is academic initiated, non-interventional research and the patients are informed and gave their permission to be part of the registry. However, no public patient's personal data was used. The basic criterion for the enrollment is objectively proven (positive CT-pulmonary angiography) acute PE. Results. The REPER was found as the single center PE registry at 2011 which enrolled patients hospitalized for the acute PE in the clinic of Internal Emergency Medicine of Military Medical Academy. As we realized that one institution could not have enough patients with acute PE to create the valid registry, we started to join other institutions under the principles of transparency and equality, and the first two were Institute for Pulmonary Diseases Vojvodina and Clinical Center Nis, which enrolled high number of patients from 2015. The registry became an international when the Clinical Center of Banja Luka joined as, followed by Clinical Center of Podgorica and Skopje. Till now, 1776 patients with acute PE are enrolled in the data base with more than 300 variables. During the last 5 years, 15 original scientific articles were published with the cumulative impact factor of 39.2, 5 doctor thesis were defended, and 5 scientific researches were presented at the ESC meeting. Conclusion. For the clinician scientist it is crucial to develop qualitative data-base with as many as possible variables which are important for the understanding pathophysiology, diagnostic process and therapy management of the disease in focus. For that it is vital to cooperate with other doctors and institutions. We think that this registry full-filled their purpose, and thanks for these data our knowledge about PE is much deeper and we become better doctors.
- 1 January 2022
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srce i krvni sudovi
- Vol. 41 (4) , 163-167
Open AccessWhat we have learned from the Regional Pulmonary Embolism Registry (REPER)?
Introduction. The management of acute pulmonary embolism (PE) is still full of controversies, and the number of randomized trials in this field is relatively small. For the individual doctor and the health system who deal with acute pulmonary embolism it is very important to analyze the number of treated patients, hospital and out of hospital mortality and morbidity, how the patients' treated, what are the most important obstacles for the management of the disease. Methods. Here, we present the Regional PE registry (REPER), in brief its development, purposes and the scientific results published in the journals on the scientific citation list, doctor thesis and studies accepted and presented at the European Society of Cardiology annual Congress. This is academic initiated, non-interventional research and the patients are informed and gave their permission to be part of the registry. However, no public patient's personal data was used. The basic criterion for the enrollment is objectively proven (positive CT-pulmonary angiography) acute PE. Results. The REPER was found as the single center PE registry at 2011 which enrolled patients hospitalized for the acute PE in the clinic of Internal Emergency Medicine of Military Medical Academy. As we realized that one institution could not have enough patients with acute PE to create the valid registry, we started to join other institutions under the principles of transparency and equality, and the first two were Institute for Pulmonary Diseases Vojvodina and Clinical Center Nis, which enrolled high number of patients from 2015. The registry became an international when the Clinical Center of Banja Luka joined as, followed by Clinical Center of Podgorica and Skopje. Till now, 1776 patients with acute PE are enrolled in the data base with more than 300 variables. During the last 5 years, 15 original scientific articles were published with the cumulative impact factor of 39.2, 5 doctor thesis were defended, and 5 scientific researches were presented at the ESC meeting. Conclusion. For the clinician scientist it is crucial to develop qualitative data-base with as many as possible variables which are important for the understanding pathophysiology, diagnostic process and therapy management of the disease in focus. For that it is vital to cooperate with other doctors and institutions. We think that this registry full-filled their purpose, and thanks for these data our knowledge about PE is much deeper and we become better doctors.
- 1 January 2020
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srce i krvni sudovi
- Vol. 39 (3) , 50-56
The use of non-vitamin K antagonists in the treatment of pulmonary thromboembolism: Nationwide experience from Serbia 2011-2019
Introduction. Pulmonary embolism (PE) is one of the major cause of hospitalization and morbidity. All studies that compared efficacy and safety of novel oral anticoagulants (NOACs) to vitamin K antagonists (VKAs) in the treatment of PE, have showed that all NOACs were equally effective as VKAs, but superior in safety. Materials and Methods. This retrospective study included 1095 of patients from the Serbian Academic Pulmonary Embolism Registry (SAPERE) with a confirmed diagnosis of PTE treated in Military Medical Academy Belgrade, Institute for Pulmonary Diseases and Institute for Cardiovascular Diseases Vojvodina, Clinical Center Niš, Kragujevac, Banja Luka, General Hospital Pančevo, Clinical Hospital Center Zemun and Zvezdara. Results. Of the 863 total patients, NOACs were therapeutic choice in 452 (52.4%) of patients.The most preferred NOAC in Military Medical Academy was Rivaroxaban, which was therapeutic choice in 117 (33.8%) of patients in this institution. On the other hand, VKAs were administered in 103 (88.0%) of patients treated in University Clinical Center Kragujevac. The use of different type of OACs was greatly influenced by the year of PE diagnosis. From 2018, VKAs are drastically less used for the treatment of PE, while the use of Rivaroxaban and Apixaban is slowly rising. The use of OACs was also influenced by the initial treatment with/without thrombolysis, value of Creatinin Clearence (CrCl) on admission, history of previous major or non-major bleeding, presence of active malignancy and HAS-BLAD score value. Conclusion. In Serbia, VKAs are still predominantly used in the treatment of PE, however, decision of the type of OAC (VKAs or NOACs) used in the treatment of this patient population greatly varies between health institutions from Serbia.
- 1 January 2020
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Srce i krvni sudovi
- Vol. 39 (3) , 50-56
The use of non-vitamin K antagonists in the treatment of pulmonary thromboembolism: Nationwide experience from Serbia 2011-2019
Introduction. Pulmonary embolism (PE) is one of the major cause of hospitalization and morbidity. All studies that compared efficacy and safety of novel oral anticoagulants (NOACs) to vitamin K antagonists (VKAs) in the treatment of PE, have showed that all NOACs were equally effective as VKAs, but superior in safety. Materials and Methods. This retrospective study included 1095 of patients from the Serbian Academic Pulmonary Embolism Registry (SAPERE) with a confirmed diagnosis of PTE treated in Military Medical Academy Belgrade, Institute for Pulmonary Diseases and Institute for Cardiovascular Diseases Vojvodina, Clinical Center Niš, Kragujevac, Banja Luka, General Hospital Pančevo, Clinical Hospital Center Zemun and Zvezdara. Results. Of the 863 total patients, NOACs were therapeutic choice in 452 (52.4%) of patients.The most preferred NOAC in Military Medical Academy was Rivaroxaban, which was therapeutic choice in 117 (33.8%) of patients in this institution. On the other hand, VKAs were administered in 103 (88.0%) of patients treated in University Clinical Center Kragujevac. The use of different type of OACs was greatly influenced by the year of PE diagnosis. From 2018, VKAs are drastically less used for the treatment of PE, while the use of Rivaroxaban and Apixaban is slowly rising. The use of OACs was also influenced by the initial treatment with/without thrombolysis, value of Creatinin Clearence (CrCl) on admission, history of previous major or non-major bleeding, presence of active malignancy and HAS-BLAD score value. Conclusion. In Serbia, VKAs are still predominantly used in the treatment of PE, however, decision of the type of OAC (VKAs or NOACs) used in the treatment of this patient population greatly varies between health institutions from Serbia.